Significance of serine proteinase and matrix metalloproteinase systems in the destruction of human articular cartilage

Clinical and Experimental Pharmacology and Physiology

Volumn 23, Issue 10-11, 1996, Pages 885-889

  Kikuchi, Hiraku ^a   Shimada, Wataru ^a   Nonaka, Tohgo ^a   Ueshima, Shigeru ^a   Tanaka, Seisuke ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cartilage; Matrix metalloproteinase; Plasminogen activator; Plasminogen activator inhibitor; Tissue inhibitor of metalloproteinase

Indexed keywords

MESSENGER RNA; METALLOPROTEINASE; SERINE PROTEINASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; ARTICULAR CARTILAGE; ENZYME ACTIVITY; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; NORTHERN BLOTTING; OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; TISSUE DEGENERATION;

EID: 0029827558     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1996.tb01138.x     Document Type: Article

References (30)

1. Dan K, Andreasen PA, Hansen JG, Kristensen P, Nielson LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 1985; 44: 139-266.
2. Okada Y, Nagase H, Harris ED Jr. A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components: Purification and characterization. J. Biol. Chem. 1989; 264: 14245-55.
3. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. Mechanism of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry 1990; 29: 10261-70.
4. Cubellis MV, Nolli ML, Cassani G, Blasi F. Binding of single-chain prourokinase to urokinase receptor of human U937 cells. J. Biol. Chem. 1986; 261: 15819-22.
5. Machovich R, Owen WG. Enzymology of plasminogen activator. Enzyme 1988; 40: 57-172.
6. Kikuchi H, Tanaka S, Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J. Rheumatol. 1987; 14: 439-45.
7. Zacharski LR, Brown FE, Memoli VA et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin. Immunol. Immunopathol. 1992; 63: 155-62.
8. Treadwell BV, Pavia M, Towle CA, Cooley TV, Mankin HJ. Cartilage synthesizes the serine protease inhibitor PAI-1: Support for the involvement of serine protease in cartilage remodeling. J. Orthop. Res. 1991; 9: 309-16.
9. Dean DD, Pelletier JM, Pelletier JP, Howell DS, Woesser JF Jr. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J. Clin. Invest. 1989; 84: 678-85.
10. Verde P, Stoppell MP, Galeffi P, Nocera PD, Blasi F. Identification and primary sequence of an unspliced human urokinase poly (A)+RNA. Proc. Natl Acad. Sci. USA 1984; 81: 4727-31.
11. Templeton NS, Brown PD, Levy AT. Cloning and characterization of human tumor cell interstitial collagenase. Cancer Res. 1990; 50: 5431-7.
12. Kerr LD, Holt JT, Matrisian LM. Growth factors regulate trans in gene expression by c-fos dependent and c-fos independent pathways. Science 1988; 242: 1424-7.
13. Durfy SJ, Clark SC, Williams BRG, Willard HF. RLFP detected by an X-linked cDNA encoding erthroid potentiating activity tissue inhibitor of metalloproteinase (EPA/TIMP). Nucl. Acids Res. 1986; 14: 9226.
14. Sterler-Stevenson, Brown PD, Onisto M, Levy AT, Liotta LA. Tissue inhibitor of metalloproteinase-2 (TIMP-2) mRNA expression in tumor cell lines and human tumor tissues. J. Biol. Chem. 1990; 265: 13933-8.
15. Tso JY, Sun XH, Kato TH, Reece KS, Wu R. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evaluation of the gene. Nucl. Acids Res. 1985; 13: 2485-97.
16. Matsuo O, Sakai T, Bando H et al. Plasminogen activator in bronchoalveolar fluid. Haemostasis 1986; 16: 43-50.
17. Loskutoff DJ, Van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc. Natl Acad. Sci. USA 1983; 80: 2956-60.
18. Chomoczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium Thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987; 162: 156-9.
19. Kummer JA, Abbink JJ, DeBoer JP et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and non-inflammatory joint diseases. Arthritis Rheum. 1992; 35: 884-93.
20. Zafarullah M, Pelletier JP, Cloutier JM, Martel-Pelletier J. Elevate metalloproteinase and tissue inhibitor of metalloproteinase mRNA in human osteoarthritic synovia. J. Rheumatol. 1993; 20: 693-7.
21. Gravallese EM, Darling JM, Ladd AL, Katz JN, Glimcher LH. In situ hybridization studies of stromelysin and collagenase messenger RNA expression in rheumatoid synovium. Arthritis Rheum. 1991; 34: 1076-89.
22. Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinase, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitive analysis and effect of corticosteroids. Arthritis Rheum. 1991; 34: 1094-105.
23. Matsuo O, Tanaka S, Kikuchi H. Effect of urinary trypsin inhibitor on osteoarthritis. Thromb. Res. 1988; 52: 237-45.
24. Bal De Kier Joffe E, Alonso DF, Puricelli L. Soluble factors released by the target organ enhance the urokinase-type plasminogen activator activity of metastatic tumor cells. Clin. Expt. Metastasis 1991; 9: 51-6.
25. Estreicher A, Muhlhauser J, Carpentier, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell. Biol. 1990; 111: 783-92.
26. Wilhelm SM, Collier IE, Kronberger A et al. Human skin fibroblast stromelysin: Structure, glycosylation, substrate specificity and differential expression in normal and tumorigenic cells. Proc. Natl Acad. Sci. USA 1987; 84: 6725-9.
27. Saus J, Quinones S, Otani Y, Nagase H, Edward DH Jr, Kurkinen M. The complete primary structure of human matrix metalloproteinase-3. J. Biol. Chem. 1988; 263: 6724-45.
28. Yagel S, Geva TL, Solomon H. High levels of human chorionic gonadotropin retard first trimester trophoblast invasion in vitro by decreasing urokinase plasminogen activator and collagenase activities. J. Clin. Endocrin. Metab. 1993; 77: 1506-11.
29. Shirasuna K, Saka M, Hayashido Y, Yoshioka H, Sugiura T, Matsuya T. Extracellular matrix production and degradation by adenoid cystic carcinoma cells: Participation of plasminogen activator and its inhibitor in matrix degradation. Cancer Res. 1993; 53: 147-52.
30. James TW, Wagner R, White LA, Zwolak RM, Brinckerhoff CE. Induction of collagenase and stromelysin gene expression by mechanical injury in a vascular smooth muscle-derived cell line. J. Cell Physiol. 1993; 157: 426-37.